The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy.

Trial Profile

The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Dec 2009

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Simvastatin
  • Indications Hypercholesterolaemia; Lipid metabolism disorders
  • Focus Therapeutic Use
  • Acronyms VICTORY
  • Most Recent Events

    • 29 Apr 2009 Actual initiation date changed from Jan 2009 to Nov 2008 as reported by ClinicalTrials.gov.
    • 29 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 29 Apr 2009 Planned end date changed from 1 Dec 2009 to 1 Jul 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top